This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Stinchcombe, T. E. Articles by Socinski, M. A. Search for Related Content PubMed Articles by Stinchcombe, T. E. Articles by Socinski, M. A.

Lung Cancer

Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer

^a Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, ^b Division of Hematology/Oncology, and ^c Division of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina, USA

Key Words. Non-small cell lung cancer • NSCLC • Combined modality therapy • Stage III • Chemotherapy • Thoracic radiation • Review

Correspondence: Thomas Stinchcombe, M.D., Multidisciplinary Thoracic Oncology Program, 3009 Old Clinic Building CB 7305, Chapel Hill, North Carolina 27599-7305, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: Thomas_Stinchcombe{at}med.unc.edu

Lung cancer remains the leading cause of cancer death in the U.S. among both men and women. Approximately 45% of patients present with stage III disease. A proportion of these patients is amenable to surgical resection; however, the majority are "unresectable." For patients with unresectable stage IIIA/B disease, thoracic radiation therapy (TRT) was considered the standard of care until the late 1980s despite a very poor 5-year survival rate. Several clinical trials demonstrated that the combination of chemotherapy and TRT was superior to TRT alone. Based on these data, combined modality therapy became the standard of care for patients with good performance status. Recent trials have shown that concurrent chemoradiotherapy offers a significant survival advantage over sequential chemoradiotherapy. Despite a substantial number of clinical trials, important questions on the optimal treatment paradigm remain. The most effective chemotherapy combination, the use of induction or consolidation chemotherapy in addition to the concurrent portion of therapy, and the optimal dose of chemotherapy with concurrent TRT have yet to be determined. The optimal total dose, fractionation, acceleration, treatment volume, and tumor targeting remain questions related to the TRT portion of therapy. Although significant progress has been made, the majority of patients experience locoregional or distant progression of their disease and die within 5 years of diagnosis. Thus, continued development and participation in clinical trials is crucial to further improvements in the treatment of patients with stage III disease.